Tinzaparin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Tinzaparin and local guidelines before prescribing.
Low molecular weight heparin
Mechanism
Low molecular weight heparin.
Uses
VTE prophylaxis and treatment.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Bleeding, HIT, injection-site bruising.
Interactions
Anticoagulants and antiplatelets.
Contraindications and cautions
Active bleeding, HIT history
Monitoring
Platelets, anti-Xa
Pregnancy and breastfeeding
Used in pregnancy
Renal and hepatic impairment
Less accumulation than other LMWHs
Overdose and reversal
Protamine partial reversal
Special advice
Preferred in renal impairment where anti-Xa monitoring is available.
More from the textbook: uses, cautions and other points
- Low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) - subcutaneous, weight-based dosing; mainly anti-Xa ; renally excreted (reduce dose with low creatinine clearance); monitor anti-Xa levels in pregnancy, extremes of weight or CKD; only partly reversed by protamine.
Cardiology: Anatomy Physiology and Pharmacology - LMWH (enoxaparin, dalteparin, tinzaparin) | Weight-based; reduce in severe kidney impairment; monitor platelets if exposed to unfractionated heparin recently (HIT); anti-Xa levels in pregnancy, kidney failure or extremes of weight
Haematology: Haemostasis and Thrombosis - Enoxaparin / tinzaparin (LMWH) | VTE prophylaxis and treatment; dose by booking weight.
Obstetrics: Medical Problems
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Haematology: Haemostasis and Thrombosis (1 mention)
- Obstetrics: Medical Problems (1 mention)